Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.11 · Revenue $35.33M · 1 analysts
Est. EPS $-0.17 · Revenue $1.90M · 1 analysts
Est. EPS $-0.30 · Revenue $45.62M · 1 analysts
Est. EPS $-0.15 · Revenue $4.63M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $12.1M | +73.4% | +24.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-99.5M | +21.8% | -34.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +85.9% | -14.1% | +9.3% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -861.3% | +56.8% | +12.5% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -819.6% | +54.9% | -7.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-56.4M | +45.6% | +28.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -464.3% | +68.6% | +42.3% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 25.9% | +89.0% | -55.2% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.99x | -62.4% | +100.8% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $141.3M | -19.5% | +58.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.29 vs -1.25 | -3.2% | -0.14 vs 0.11 | -227.3% |
| Revenue Surprise | $12.1M vs $17.5M | -30.6% | $5.7M vs $35.3M | -83.9% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | Non-Qualified Stock Option (right to buy) | A | 38,000 | $3.94 |
| Jun 9, 2026 | Dorton Katina | director | Director Stock Option (Right to Buy) | A | 38,000 | $3.94 |
| Jun 9, 2026 | Babler Martin | director | Director Stock Option (Right to Buy) | A | 38,000 | $3.94 |
| Jun 9, 2026 | Bonita David P | director, 10 percent owner: | Director Stock Option (Right to Buy) | A | 38,000 | $3.94 |
| Jun 9, 2026 | Sandor Victor | director | Director Stock Option (Right to Buy) | A | 38,000 | $3.94 |
Operator: Good morning, everyone, and welcome, everyone, to the Prelude Therapeutics Investor Conference Call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now turn the call over to Prelude's Chief Financial Officer and Chief Legal Officer, Bryant Lim. Please go ahead. Bryant Lim: Thank you, operator. During today's call, we will make forward-looking statements based on current expectations, including statements concerning anticipated discovery, preclinical and future clinical development activities for our product candidates; the potential safety, efficacy, benefits and addressable market for our product candidates and clinical trial results for our product candidates; together with other statements regarding our plans, prospects and expectations. Such statements represent our judgments as of today, are not promises or guarantees, and as you know, may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Please refer to our filings with the SEC, which are available through the Investor Relations section of our website for information concerning risk factors that may affect the company. We undertake no obligation to update forward-looking statements, except as required by law. During this call, we will also be referring to certain slides from our corporate presentation that are available on the Investors section of our corporate website under Presentations and Events. Also on this call are Kris Vaddi, Prelude's Founder and Chief Executive Officer; as well as Peggy Scherle, our Chief Scientific Officer; and Sean Brusky, our Chief Business Officer. I will now turn the call over to Kris to kick things off. Krishna Vaddi: Thank you, Bryant, and good morning to everyone joining us today. Over the past quarter, we've made a series of strategic decisions designed to sharpen our R&D focus, optimize our capital allocation and align our business strategy with programs that we believe offer the highest probability of success. These steps strengthen our ability to deliver on our mission, to discover and develop transformative medicines that can meaningfully improve patient outcomes in cancer. Importantly, as part of these efforts, we've also enhanced our financial position, providing us with additional cash runway to advance our lead programs into clinical development. Looking ahead, our primary focus will be on rapidly advancing 2 development candidates that we believe represent compelling opportunities for our investors with both programs expected to enter the clinic in 2026. The first is a JAK2V617F selective inhibitor for myeloproliferative neoplasms or MPN. The second is a KAT6A selective degrader for ER-positive breast cancer. Both of these programs target clinically validated pathways and have the potential to demonstrate efficacy and safety differentiation in early clinical development. In addition, we believe that these …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Krishna Vaddi | Founder, Chief Executive Officer & Director | USD 935,256 | — | 1966 | Active |
Bryant David Lim | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | USD 681,050 | Male | 1971 | Active |
Peggy A. Scherle | Chief Scientific Officer | USD 674,206 | — | 1962 | Active |
Andrew Combs | Executive Vice President & Chief Chemistry Officer | USD 562,461 | — | 1967 | Active |
Robert A. Doody Jr. | Senior Vice President of Investor Relations | — | Male | — | Active |
Aimee Crombie | Senior Vice President and Head of Strategic Planning & Operations | — | Female | — | Active |
Michele Porreca | Chief People Officer | — | Female | — | Active |
Madhu Pudipeddi | Senior Vice President of Technical Operations | — | — | — | Active |
Naveen Babbar | Senior Vice President of Translation Medicine | — | Male | — | Active |
Wan-Jen Hong | Senior Vice President of Clinical Development | — | — | 1979 | Active |
The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ADAR1 Capital Management LLC purchased a new position in shares of Prelude Therapeutics Incorporated (NASDAQ: PRLD) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 152,825 shares of the company's stock, valued at approximately $523,000. ADAR1 Capital Management
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
